Efficacy and safety of Xinnaoning capsule in treating chronic stable angina (qi stagnation and blood stasis syndrome): Study protocol for a multicenter, randomized, double-blind, placebo-controlled trial

Jun-Nan Zhao, Ying Zhang, Xu Lan, Yao Chen, Jing Li, Ping Zhang, Li-Qi Wu, Shu-Ting Jia, Yue Liu, Feng-Qin Xu, Jun-Nan Zhao, Ying Zhang, Xu Lan, Yao Chen, Jing Li, Ping Zhang, Li-Qi Wu, Shu-Ting Jia, Yue Liu, Feng-Qin Xu

Abstract

Background: Chronic stable angina (CSA) is a cardiovascular disease with high prevalence. At present, drug treatment is still the main measure of stable angina pectoris. Traditional Chinese medicine has a long history in the treatment of CSA. Qi stagnation and Blood stasis syndrome is a common syndrome of CSA. Xinnaoning (XNN) capsule is considered as an effective adjuvant treatment for CSA with the efficacy of promoting qi and blood circulation but lack of high-quality clinical evidence. The purpose of this study is to evaluate the efficacy and safety of XNN capsule compared with placebo by clinical trial.

Methods: This multicenter, randomized, double-blind, placebo-controlled trial will be conducted with a total of 240 participants diagnosed with chronic stable angina (qi stagnation and blood stasis syndrome). The participants will be randomized (1:1) into groups receiving either XNN or placebo for 12 weeks. After a 2-week run-in period, they will receive either XNN or placebo (3 pills, 3 times daily) for 12 weeks on the basis of conventional therapy. The primary outcomes include changes in the integral scores of angina symptoms. The secondary outcome measures include changes in the total score of traditional Chinese medicine syndrome, severity grading of angina pectoris, the number of angina pectoris per week, nitroglycerin dosage, score of seattle angina scale, serum homocysteine, incidence of cardiovascular events. Safety outcomes will also be assessed. Adverse events will be monitored throughout the trial.

Results: This study will investigate whether XNN capsule can alleviate clinical symptoms, and improve quality of life of patients with chronic stable angina (qi stagnation and blood stasis syndrome). The results of this study will provide clinical evidence for the application of XNN capsule in the treatment of chronic stable angina.

Trial registration: ClinicalTrials.gov: NCT03914131.

Conflict of interest statement

The authors report no conflicts of interest.

Figures

Figure 1
Figure 1
Trial flow chart.

References

    1. Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics—2018 update: a report from the American Heart Association. Circulation 2018;137:67–492.
    1. Khot AM, Anuradha HV, Prakash VS, et al. Antianginal efficacy and tolerability of ranolazine as an add-on drug to concomitant medications primarily metoprolol in chronic stable angina patients: a prospective, open-label study. J Pharmacol Pharmacother 2017;8:21–7.
    1. Ma D, Sakai H, Wakabayashi C, et al. The prevalence and risk factor control associated with noncommunicable diseases in China, Japan, and Korea. J Epidemiol 2017;27:568–73.
    1. Chaitman BR, Laddu AA. Stable angina pectoris: antianginal therapies and future directions. Nat Rev Cardiol 2011;9:40–52.
    1. Thadani U. Management of stable angina—current guidelines: a critical appraisal. Cardiovasc Drugs Ther 2016;30:419–26.
    1. Gao ZY, Xu H, Shi DZ, et al. Analysis on outcome of 5284 patients with coronary artery disease: the role of integrative medicine. J Ethnopharmacol 2012;141:578–83.
    1. Xiong JX, Wang Z, Wang J. Innovative strategy in treating angina pectoris with Chinese patent medicines by promoting blood circulation and removing blood stasis: experience from combination therapy in Chinese medicine. Curr Vasc Pharmacol 2015;13:540–53.
    1. Yi GZ, Qiu YQ, Xiao Y, et al. The usefulness of xuefu zhuyu tang for patients with angina pectoris: a meta-analysis and systematic review. Evid Based Complement Alternat Med 2014;2014:521602.
    1. Qiu Y, Xu H, Shi D. Traditional chinese herbal products for coronary heart disease: an overview of cochrane reviews. Evid Based Complement Alternat Med 2012;2012:417387.
    1. Cheng CW, Wu TX, Shang HC, et al. CONSORT extension for Chinese herbal medicine formulas 2017: recommendations, explanation, and elaboration (traditional Chinese version). Ann Intern Med 2017;167:7–20.
    1. The Chinese medical association cardiovascular branch. Guideline for diagnosis and treatment of patients with chronic stable angina. Chin J Cardiol 2007;35:195–206.
    1. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012;126:3097–137.
    1. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34:2949–3003.
    1. Campeau L. Letter: grading of angina pectoris. Circulation 1976;54:522–3.
    1. China Food and Drug Administration. Technical guidelines for clinical research on the treatment of angina pectoris by traditional Chinese medicine and natural medicine. Available at: .
    1. Padala SK, Lavelle MP, Sidhu MS, et al. Antianginal therapy for stable ischemic heart disease: a contemporary review. J Cardiovasc Pharmacol Ther 2017;22:499–510.
    1. Wang JR, Cao SJ, Wang GJ. Clinical efficacy of Xinnaoning capsule in the treatment of unstable angina pectoris of coronary heart disease. Chin Clin Doctor 2016;44:47–9.
    1. Leng L, Ma YY. Clinical study of Xinnaoning capsule combined with clopidogrel in the treatment of unstable angina. Drugs Clin 2017;32:415–8.
    1. Yu ML, Gao X, Xu H. Progress of Xinnaoning capsule in the prevention and treatment of cardiovascular and cerebrovascular diseases. Chin J Integr Med Cardio/Cerebrovasc Dis 2017;15:2835–7.
    1. Yu ML, Zhang H, Zhang Y, et al. Systematic evaluation of randomized controlled trials of Xinnaoning capsule in the treatment of coronary heart disease and angina pectoris. Chin J Integr Med Cardio/Cerebrovasc Dis 2018;16:678–83.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj